Genmab (GMAB) awards new RSUs and warrants under long-term incentive plans
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Genmab A/S reports that its Board of Directors has granted 15,894 restricted stock units and 15,494 warrants to employees of the company and its subsidiaries. Each restricted stock unit is awarded cost-free, has a fair value equal to the DKK 1,616.50 closing share price on the grant date, and will vest after three years, subject to program conditions.
Each warrant is also awarded cost-free, carries an exercise price of DKK 1,616.50 per share and a calculated fair value of DKK 534.23 using the Black-Scholes formula. The warrants vest three years after grant and expire seven years after the grant date, under Genmab’s existing warrant program.
Positive
- None.
Negative
- None.
Key Figures
Restricted stock units granted: 15,894 units
Warrants granted: 15,494 warrants
RSU fair value: DKK 1,616.50 per unit
+4 more
7 metrics
Restricted stock units granted
15,894 units
Employee equity awards, June 11, 2026
Warrants granted
15,494 warrants
Employee equity awards, June 11, 2026
RSU fair value
DKK 1,616.50 per unit
Equal to closing Genmab share price on grant date
Warrant exercise price
DKK 1,616.50 per share
Exercise price for each employee warrant
Warrant fair value
DKK 534.23 per warrant
Calculated using Black-Scholes formula
Vesting period
3 years
Applies to both RSUs and warrants from grant date
Warrant expiry
7 years from grant
Expiration of employee warrants
Key Terms
restricted stock unit, warrants, Black-Scholes formula, forward looking statements, +1 more
5 terms
restricted stock unit financial
"decided to grant 15,894 restricted stock units and 15,494 warrants to employees"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
warrants financial
"decided to grant 15,894 restricted stock units and 15,494 warrants to employees"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
Black-Scholes formula financial
"By application of the Black-Scholes formula, the fair value of each warrant can be calculated"
forward looking statements regulatory
"This Company Announcement contains forward looking statements."
Statements about a company’s expected future performance, plans, goals, or projections that are not historical facts and involve assumptions and estimates. Investors care because these are predictions that guide decisions but can be wrong; like a weather forecast, they help set expectations and risk — if circumstances change, actual results may differ significantly, so investors should weigh them alongside hard data and risk factors.
Annual Report on Form 20-F regulatory
"risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings"
An annual report on Form 20-F is a standardized filing that foreign companies submit to the U.S. securities regulator to disclose their financial results, business operations, risks, and management’s discussion of performance. It matters to investors because it provides a complete, audited snapshot—like a company’s financial report card and shareholder letter combined—used to assess transparency, compare companies, and judge whether the stock’s price matches underlying business strengths and risks.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF JUNE 2026
COMMISSION FILE NUMBER 001-38976
Genmab A/S
(Exact name of Registrant as specified in its charter)
(Exact name of Registrant as specified in its charter)
Carl Jacobsens Vej 30
2500 Valby
Denmark
+45 70 20 27 28
(Address of principal executive offices)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F
This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit | Description of Exhibit | ||||
| 99.1 | Company Announcement Dated June 11, 2026: Grant of Restricted Stock Units and Warrants to Employees in Genmab | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GENMAB A/S | ||||||||
| BY: | /s/ Anthony Pagano | |||||||
| Name: Anthony Pagano | ||||||||
| Title: Executive Vice President & Chief Financial Officer | ||||||||
DATE: JUNE 11, 2026
Exhibit 99.1
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement
COPENHAGEN, Denmark; June 11, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 15,894 restricted stock units and 15,494 warrants to employees of the Company and the Company's subsidiaries.
Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 1,616.50.
The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units.
The exercise price for each warrant is DKK 1,616.50. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 534.23.
The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the Board of Directors on February 23, 2021. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Governance > Compensation > Warrants.
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 29 Page 1/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
Grant of Restricted Stock Units and Warrants to Employees in Genmab
This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 29 Page 2/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
FAQ
What equity awards did Genmab (GMAB) grant to employees in June 2026?
Genmab granted 15,894 restricted stock units and 15,494 warrants to employees. These awards form part of the company’s long-term incentive programs, aligning employee compensation with shareholder value through future share delivery and potential share subscriptions.
What are the key terms of Genmab (GMAB) restricted stock units granted in 2026?
Each restricted stock unit is granted cost-free and gives a conditional right to one Genmab share of nominally DKK 1. They have a fair value of DKK 1,616.50 each and vest after three years, subject to program-specific vesting conditions set by the Board.
What are the main features of the Genmab (GMAB) employee warrants granted?
Each warrant entitles the holder to subscribe for one share of nominally DKK 1 at an exercise price of DKK 1,616.50. Using the Black-Scholes formula, fair value is DKK 534.23 per warrant. Warrants vest after three years and expire seven years from grant.
How long is the vesting period for Genmab (GMAB) 2026 equity awards?
Both restricted stock units and warrants granted vest three years after the grant date. RSUs vest on the first banking day of the month following the three-year period, while warrants vest at three years and then remain exercisable until their seven-year expiry.
Where can investors find more details on Genmab (GMAB) compensation programs?
Details on Genmab’s restricted stock unit program are available at genmab.com under Investors > Governance > Compensation > Restricted Stock Units. Information on warrant schemes is found under Investors > Governance > Compensation > Warrants, outlining program terms and conditions.
Does this Genmab (GMAB) announcement include forward looking statements?
The announcement includes forward looking statements identified by words like “believe,” “expect,” and “anticipate.” Genmab notes that actual results may differ materially due to clinical, manufacturing, market, competitive, personnel, intellectual property, and technological risks described in its latest reports and SEC filings.